scorecardresearchICICI Securities sees 39% upside in Natco Pharma despite sharp fall this year. Here's why

ICICI Securities sees 39% upside in Natco Pharma despite sharp fall this year. Here's why

Updated: 16 Nov 2022, 08:22 AM IST
TL;DR.
ICICI Securities remains bullish on Natco Pharma with a ‘buy’ call and a target price of 816 per share, implying an upside of 39.29 percent.
For the September quarter, Natco Pharma reported a 12.74% drop in its consolidated net profit to  <span class='webrupee'>₹</span>56.8 crore, compared to  <span class='webrupee'>₹</span>65.1 crore in the corresponding quarter of last year.

For the September quarter, Natco Pharma reported a 12.74% drop in its consolidated net profit to 56.8 crore, compared to 65.1 crore in the corresponding quarter of last year.